Curcumin

Curcumin is the principal active compound in turmeric (Curcuma longa) and is studied across the same indications as turmeric extracts but at standardized higher curcuminoid concentrations. The clinical literature spans osteoarthritis (where the supplement has umbrella-meta-analysis-level evidence for symptomatic benefit), inflammatory and antioxidant biomarkers, lipid profiles, type 2 diabetes-related markers, depression and other mood conditions, ulcerative colitis, and many smaller research areas. Curcumin's mechanisms span inflammation (NF-kB, COX-2 modulation), antioxidant activity, and effects on multiple cellular signaling pathways - which is the conceptual basis for its unusually broad indication base.

The outcome dimensions covered most heavily are osteoarthritis (a widely promoted consumer use, where umbrella meta-analyses synthesize multiple individual trials), inflammatory and antioxidant biomarkers (the mechanistic foundation underlying most claimed benefits), lipid profile improvements (consistent across many trials), metabolic markers in type 2 diabetes and metabolic syndrome, and mood including depression. The 2024 synthesis across 103 RCTs and 42 outcomes, with a 2025 umbrella review of meta-analyses, is the closest the field has to a supplement-overall reference.

Demographically, the literature is unusually broad across populations and conditions, reflecting curcumin's pleiotropic mechanism. The single most-practical question for curcumin specifically is bioavailability: standard curcumin has very poor oral absorption (about 1% in a rat study), which is why many modern supplemental products use one of several absorption-enhancement strategies: piperine co-administration (common and low cost), phospholipid complexes (Meriva), micellar formulations, gamma-cyclodextrin complexes, or nanoparticle or solid-lipid-particle delivery (Theracurmin, Longvida). Trial results depend substantially on which formulation was used, with reported bioavailability gains ranging from under 10-fold to more than 100-fold between products.

Curcumin is generally well-tolerated at typical supplemental doses; NCCIH describes conventional formulations as likely safe for up to 2 or 3 months. The most-common adverse effects are gastrointestinal: nausea, abdominal discomfort, and diarrhea at higher doses. Curcumin supplements are a documented, though rare, cause of drug-induced liver injury, most often with absorption-enhanced formulations; pharmacovigilance reports from multiple countries document cases, though absolute risk appears low. Drug interactions include theoretical additive effects with anticoagulants (curcumin affects platelet function), possible reduced absorption of iron (seen in laboratory work, not confirmed in human trials), and a debated interaction with chemotherapy agents in oncology contexts. People with gallstones or liver disease, who are pregnant, on anticoagulants, or undergoing chemotherapy should consult a clinician.

This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.